TScan Therapeutics (TCRX) Total Current Liabilities (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Total Current Liabilities data on file, last reported at $20.0 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 33.02% year-over-year to $20.0 million in Q1 2026; TTM through Mar 2026 was $20.0 million, a 33.02% decrease from a year earlier, with the FY2025 full-year figure at $18.7 million, down 48.01% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $20.0 million, up from $18.7 million in the prior quarter.
• Over the last five years, Total Current Liabilities for TCRX reached as high as $38.6 million in Q2 2024 and fell as low as $14.0 million in Q1 2023.
• Historically, Total Current Liabilities has averaged $26.2 million across 5 years, with a median of $29.2 million in 2025.
• Across the five-year window, Total Current Liabilities surged 124.1% in 2024 and sank 48.01% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $17.3 million in 2022, then surged by 72.32% to $29.8 million in 2023, then gained by 20.58% to $36.0 million in 2024, then sank by 48.01% to $18.7 million in 2025, then climbed by 6.82% to $20.0 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $20.0 million in Q1 2026, $18.7 million in Q4 2025, and $29.2 million in Q3 2025.